Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial | Zendy

Suparna Chatterjee | Zendy; Tuhin Kanti Biswas | Zendy; Arup Dutta | Zendy; G Sengupta | Zendy; Anupam Mitra | Zendy; Soumi Kundu | Zendy

Open Access

Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial

Author(s) -

Suparna Chatterjee,

Tuhin Kanti Biswas,

Arup Dutta,

G Sengupta,

Anupam Mitra,

Soumi Kundu

Publication year - 2011

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.75667

Subject(s) - cefpodoxime , exacerbation , medicine , chronic bronchitis , gemifloxacin , bronchitis , tolerability , randomized controlled trial , adverse effect , clinical trial , antibacterial agent , antibiotics , microbiology and biotechnology , biology

Acute exacerbation of chronic bronchitis (AECB) is a commonly encountered problem and those suspected to be due to bacterial infections require antibiotic therapy. This randomized, controlled trial was designed to evaluate the effectiveness and safety of gemifloxacin, a new fluoroquinolone, versus cefpodoxime, an oral third-generation cephalosporin, for the treatment of mild to moderately severe cases of AECB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research